The number of U.S. employers paying for obesity drugs, including Novo Nordisk’s Wegovy, which belongs to the GLP-1 class of drugs, could nearly double next year, according to a survey. The survey of 502 employers by Accolade, a company that provides health plans for employers, and research firm Savanta found that 43% of employers surveyed could pay for GLP-1 drugs in 2024, up from 25% who cover them now.